Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Raman spectroscopy model can distinguish between CLL and DLBCL

Publish date:: August 17, 2020

Key clinical point: CLL model and DLBCL model both have high sensitivity and specificity.

Major finding: Combination of 1445 cm^-1 and 1655 cm^-1 could discriminate DLBCL from CLL.

Study details: Analysis of blood plasma from 33 DLBCL patients, 39 CLL patients, and 30 healthy volunteers.

Disclosures: The study was supported by the National Natural Science Foundation of China. The authors reported that they had no competing interests.

Citation:

Bai Y et al. Journal of Pharmaceutical and Biomedical Analysis. 2020; doi.org/10.1016/j.jpba.2020.113514.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in DLBCL

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,

Survey quantifies COVID-19’s impact on oncology,

Sarcopenia is a predictor of overall survival in DLBCL patients,

Mutation tied to central nervous system collapse in DLBCL,